Peptide Drug Development Services

Structure of peptides

A blood-tumor barrier (BTB) on brain tumor vessels severely limits the reach of hydrophilic chemotherapeutic drugs to tumor tissue. Therefore, the application of drugs that selectively open the BTB may be the key to improving the efficacy of brain tumor patients. And peptides have unique advantages as drugs with small molecular weight, non-immunogenicity, good tissue permeability, high affinity, and low side effects. And the solid phase chemical synthesis of peptides makes the production cost lower than other biological drugs.

Peptide drug development service for the brain tumors that we provide

The direction of any drug development is whether this drug can exert an effective drug action at an adequate time and at a specific site. Alfa Cytology provides our clients with brain tumor peptide development services that are highly pure and safe. We believe that more and more active anti-brain tumor peptides will enter the clinic and bring new hope for the treatment of brain tumors.

The peptides we offer for drug development

Category	Function
Tumor necrosis inducing active peptides	Peptides that induce brain tumor necrosis have a higher selectivity for brain tumor cells compared to conventional chemotherapeutic agents. In addition, these peptides can kill cancer cells that are resistant to chemotherapy using membrane lysis.
Apoptosis-active peptides	Cancer cells have a higher threshold for responding to apoptotic signals than normal cells, and therefore tumor cells can escape apoptosis. This makes apoptosis-inducing peptides a priority drug for development in anti-brain tumor therapy.
Receptor antagonist peptide	Small molecule peptides that compete with brain tumor cell surface hormone receptors for binding ligands, including bradykinin. Small doses of bradykinin can selectively increase the permeability of BTB with little effect on the blood-brain barrier (BBB) of normal brain tissue. The ability of bradykinin to selectively and reversibly open the BTB is important for the efficacy of brain tumor drugs.
Cell adhesion factor antagonist peptides	Cell adhesion inhibitory peptides can affect the binding of extracellular matrix (ECM) to tumor cells and play an important role in tumor metastasis and angiogenesis. One of these RGD peptides can be used for glioma-targeted therapy. In addition to direct use, this includes coupling with other biomolecules or vectors, including peptides, protein and nucleic acid-based biomolecules, adenoviral vectors, polymeric nanoparticles, liposomes, and radiopharmaceuticals.
Protein kinase inhibitory peptides	Protein kinases are very active in cancer cells and this has become one of the targets for brain tumor therapy.
Anti-angiogenic peptides	We are looking for small peptides that are functionally similar to large endogenous angiogenesis inhibitory proteins or peptides for our clients. To overcome the disadvantage that traditional endogenous angiogenesis inhibitors have poor tissue permeability and are easily cleared away.
Immune-activating peptides	Immune adjuvants can be used to activate the body's intrinsic and specific immune response during brain tumor treatment.

Peptide profiling analysis

With our peptide profiling analysis service, clients can not only confirm primary amino acid sequences but also identify and quantify post-translational modifications (PTM) such as deamidation, oxidation, truncation, phosphorylation, methylation, nitrosation, ubiquitination, lipidation, glycosylation, and isomerization. Our team of experts has created UPLC peptide analysis solutions that take into account many aspects of peptide analysis.

Peptide chemical synthesis services

We can provide our customers with services such as the customization of peptide API intermediates. We will process and synthesize peptides with different sequences, purity, and molecular weight according to the different requirements of customers, and provide RGD peptide and RAD peptide customization services.

Peptide modification services

Chemical modification. Fluorescence modification (FITC, FAM), Biotin labeling, methylation, acetylation, amidation, fatty acid, and phosphorylation modification
Cyclic peptides. Amide ring, disulfide-bonded ring
Protein coupling (KLH, BSA, OVA)
Containing special amino acids (D-type, various amino acid derivatives)
Raw pharmaceutical peptide
Complex antigenic peptide (MAP)

Anti-brain tumor peptide activity enhancement strategy

Amino acid substitution method. Amino acid substitution and cyclization modifications.
Synthesis of mimetic peptides. Combining two peptides to obtain a novel peptide with enhanced anti-brain tumor ability.

In addition, Alfa Cytology has made it possible to make more peptides into anti-brain tumor drugs by introducing a ring structure to restrain the activity of the peptide and increase the stability of the peptide to show better pharmacological activity and stability. Please contact our staff to learn how we can provide you with peptides for brain tumor research.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.